To help persuade decision-making entities to make the atypical hemolytic uremic syndrome (aHUS) treatment Ultomiris (ravulizumab) available in countries with socially funded healthcare, aHUS Alliance Global Action is asking patients and caregivers worldwide to contribute their experience with the therapy. The organization is seeking input about the…
News
When the COVID-19 pandemic forced the postponement of a rare disease film festival originally slated for May, its organizers set out to find a new way to bring the films to an audience. Co-founders Daniel DeFabio and Bo Bigelow, who are both fathers of children with…
The rejection of a kidney transplant was found to be the cause of intestinal bleeding and pain in a woman with atypical hemolytic uremic syndrome (aHUS) without systemic symptoms. A report describing that case, “Isolated thrombotic…
Mutations leading to the overactivation of the complement regulator protein C3 should be recognized as a cause of atypical hemolytic uremic syndrome (aHUS), a case report highlights. The report, “Complement C3 mutation causing atypical hemolytic uremic syndrome successfully treated with eculizumab,” was published in the…
A rare type of inflammatory arthritis known as Still’s disease may trigger the development of atypical hemolytic uremic syndrome (aHUS), a recent case report suggests. A timely diagnosis of these conditions is critical to avoid irreparable damage to organs, the authors warn. The report, “Aggressive…
Atypical hemolytic uremic syndrome (aHUS) can co-exist with autoimmune thyroid disease, and the two conditions may influence each other’s development, a case report suggests. The report, “Atypical hemolytic uremic syndrome precipitated by thyrotoxicosis: a case report,” was published in BMC Pediatrics. Autoimmune thyroid disease (AITD)…
The EveryLife Foundation for Rare Diseases has launched a nationwide National Burden of Rare Disease Survey to measure the full implications, economic and social, of living with rare disease in the United States. People with rare diseases know that the impacts of such conditions extend beyond just medical…
Self-administering Ultomiris (ravulizumab) as weekly under-the-skin injections may be as safe and effective in preventing overactivation of the complement system as standard intravenous infusions (given directly into the bloodstream), according to interim data from a Phase 3 clinical trial. Excessive activation of the complement system — a set…
Alexion Pharmaceuticals announced that Ultomiris (ravulizumab) has been approved in the European Union to treat adults and children (weighing at least 10 kgs, or 22 lbs) with atypical hemolytic uremic syndrome (aHUS). “Today’s marketing authorization marks an important step in our efforts to establish Ultomiris as the…
A short film by Kidney Research UK looking at how scientific research has helped those with atypical hemolytic uremic syndrome (aHUS) garnered People’s Choice honors at this year’s Charity Film Awards, presented virtually due to the COVID-19 outbreak. Called “Saving Lives — How Genetics Research Changed the…
Recent Posts
- Inflammation of the pancreas may trigger aHUS, boy’s case shows
- Patients need more help to pay for rare disease treatment
- Man’s psoriasis triggers kidney failure, aHUS in rare overlap
- How inflammation from multiple conditions led to an eye emergency
- Early treatment critical in aHUS to prevent lasting kidney damage
- I struggle daily with deconditioning from my multiple illnesses
- Complement inhibitors show edge over plasma at stopping aHUS relapses
- Boy’s kidney issues resolve after Soliris treatment: Case report
- I’m learning to say, ‘There’s always tomorrow’ when I’m feeling guilty
- Rare aHUS after kidney transplant successfully treated with Soliris